الصفحة الرئيسية>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Briciclib

Briciclib (Synonyms: ON-014185)

رقم الكتالوجGC19083

Briciclib (ON 014185) هو مشتق من ON 013100 ، ولديه القدرة على استهداف eIF4E للسرطانات الصلبة

Products are for research use only. Not for human use. We do not sell to patients.

Briciclib التركيب الكيميائي

Cas No.: 865783-99-9

الحجم السعر المخزون الكميّة
1mg
52٫00
متوفر
5mg
103٫00
متوفر
10mg
161٫00
متوفر
50mg
631٫00
متوفر
100mg
1062٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Briciclib is a water soluble derivative of ON 013100, and has the potential in targeting eIF4E for solid cancers.

Briciclib has the potential in targeting eIF4E. Briciclib shows inhibitory activity against the proliferation of mantle cell leukemia (EKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines with GI50s of 9.8-12.2 nM, and with no toxicity on normal endothelial cells. Briciclib dose-dependently reduces the expression of cyclin D1 and c-Myc in breast and MCL cancer cell lines within 8 hours[1].

References:
[1]. Neel Jasani, et al. Abstract 1649: Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent. Cancer Research. August 2015, Volume 75, Issue 15.

مراجعات

Review for Briciclib

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Briciclib

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.